General Hospital Krusevac

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease2 trials
• IgA nephropathy1 trial
• Lupus (SLE)1 trial
• Stroke1 trial
• Type 1 diabetes1 trial
• Type 2 diabetes1 trial

Phase

• Phase 23 trials
• Phase 31 trial

Status

• Completed2 trials
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• Amgen1 trial
• Eli Lilly and Company1 trial
• HI-Bio, A Biogen Company1 trial
• Inversago Pharma Inc.1 trial

Running trials

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

  Contact: Branislav Andric (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• Stroke1 recruiting

Closed trials

• Terminated

  Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

  NCT05540665· Phase 2· Amgen· Source

• Completed

  Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

  NCT05514548· Phase 2· Inversago Pharma Inc.· Source

• Completed

  Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

  NCT05065970· Phase 2· HI-Bio, A Biogen Company· Source